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Myelin-specific induction of tolerance represents a promising means to modify the course
of autoimmune inflammatory demyelinating diseases such as multiple sclerosis (MS).
Our laboratory has focused on a novel preclinical strategy for the induction of tolerance
to the major encephalitogenic epitopes of myelin that cause experimental autoimmune
encephalomyelitis (EAE) in rats and mice. This novel approach is based on the use of
cytokine-NAg (neuroantigen) fusion proteins comprised of the native cytokine fused either
with or without a linker to a NAg domain. Several single-chain cytokine-NAg fusion proteins
were tested including GMCSF-NAg, IFNbeta-NAg, NAgIL16, and IL2-NAg. These cytokine-
NAg vaccines were tolerogenic, therapeutic vaccines that had tolerogenic activity when
given as pre-treatments before encephalitogenic immunization and also were effective as
therapeutic interventions during the effector phase of EAE. The rank order of inhibitory
activity was as follows: GMCSF-NAg, IFNbeta-NAg>NAgIL16> IL2-NAg>MCSF-NAg,
IL4-NAg, IL-13-NAg, IL1RA-NAg, and NAg. Several cytokine-NAg fusion proteins exhibited
antigen-targeting activity. High affinity binding of the cytokine domain to specific cytokine
receptors on particular subsets of APC resulted in the concentrated uptake of the NAg
domain by those APC which in turn facilitated the enhanced processing and presentation
of the NAg domain on cell surface MHC class II glycoproteins. For most cytokine-NAg
vaccines, the covalent linkage of the cytokine domain and NAg domain was required for
inhibition of EAE, thereby indicating that antigenic targeting of the NAg domain to APC
was also required in vivo for tolerogenic activity. Overall, these studies introduced a new
concept of cytokine-NAg fusion proteins as a means to induce tolerance and to inhibit the
effector phase of autoimmune disease.The approach has broad application for suppressive
vaccination as a therapy for autoimmune diseases such as MS.
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INTRODUCTION: IMMUNOLOGICAL TOLERANCE TO CNS
MYELIN AS A THERAPY FOR MS
Multiple sclerosis (MS) is an inflammatory demyelinating disease
of the CNS (Nylander and Hafler, 2012). A defining hallmark of
the disease is the formation of multiple discrete inflammatory
lesions and focal demyelination in perivascular and periventricular
sites of CNS white matter. These demyelinating lesions are marked
by infiltration of activated mononuclear cells and are associated
with the appearance of neurologic deficits. MS is also marked by
Abbreviations: DC, dendritic cell(s); EAE, experimental autoimmune
encephalomyelitis; GM-CSF, granulocyte-macrophage colony-stimulating fac-
tor; IFN, interferon; MBP, myelin basic protein; MHCII, major histocompatibility
complex class II; MOG, myelin oligodendrocyte glycoprotein; MS, multiple
sclerosis; NAg, neuroantigen(s); PLP, proteolipid protein.
significant involvement in CNS gray matter with axonal loss, corti-
cal atrophy, and cognitive dysfunction (Calabrese et al., 2011). MS
is considered to be an autoimmune disorder caused by T cells spe-
cific for immunodominant self-epitopes of myelin and other CNS
antigens (Severson and Hafler, 2010). These autoreactive T cells
are postulated to migrate across the blood-brain barrier into the
CNS and undergo re-activation upon T cell antigen recognition
of endogenous CNS epitopes. These activated T cells then secrete
pro-inflammatory cytokines and chemokines to recruit inflamma-
tory macrophages and other leukocytes from the blood to initiate
focal demyelination and CNS dysfunction.
A central goal for the field of autoimmunity is to opti-
mize strategies of antigen-specific tolerance induction as a ther-
apy for chronic autoimmune disorders (Leech and Anderton,
2008; Sabatos-Peyton et al., 2010; Nepom et al., 2011). The goal
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is to derive antigen-specific vaccines to generate a suppressive
immunological memory specific for particular target self-antigens.
Realization of this goal will provide a potentially curative interven-
tion that would reverse the pathological autoimmune response
and thereby preempt the need for chronic administration of
broad-spectrum immunosuppressive drugs. Thus, new tolero-
genic strategies are needed to maximize reliability and efficiency
of antigen-specific tolerogenic vaccines that may be amenable for
use in humans.
Strategies of myelin-specific tolerance induction may thereby
provide a means to develop more effective therapies for MS.
Tolerogenic vaccine strategies would be disease-specific and would
be based on the imposition of regulatory constraints on the dom-
inant pathogenic clones responsible for MS. However, substantial
hurdles exist. First and most importantly, the field currently lacks
a valid and reliable means to induce myelin-specific tolerance in
patients afflicted with MS. Second, myelin-specific tolerance regi-
mens must not lead to inadvertent encephalitogenic sensitization,
autoantibody formation, or anaphylactic sensitivity. Third, MS in
different patients may be driven by autoreactivity against unique
and perhaps non-overlapping sets of pathogenic myelin epitopes.
Fourth, during the course of disease, “epitope-spreading” may
generate an ever broadening polyclonal repertoire that targets an
expanding multiplicity of myelin epitopes. Lastly, MS may tran-
sition from an immunological inflammatory disease amenable to
immunological intervention to a neurodegenerative disease resis-
tant to immunomodulatory approaches. Meaningful solutions to
these challenges will stem from new technologies that profile the
myelin-specific T cell specificities early during the course of dis-
ease coupled with new strategies to reliably induce tolerance to
those myelin epitopes. Thus, an important part of this strategy
will be to engineer immunosuppressive vaccines based on a robust
platform that can induce reliable and potent tolerance in both non-
inflammatory and overtly inflammatory environments. Despite
the hurdles, myelin-specific induction of immunological toler-
ance represents the most promising path to specifically modify the
course of autoimmune inflammatory demyelinating disease and
thereby circumvent the need for broad-spectrum immunosup-
pression. Myelin-specific tolerance regimens promise qualitative
improvements in clinical efficacy, therapeutic longevity, and cost-
effectiveness without the adverse consequences of a compromised
immune system.
Experimental autoimmune encephalomyelitis (EAE) repre-
sents a widely used preclinical model to test tolerogenic vac-
cines as candidates for potential translation for treatment of
MS (Wekerle, 2008). EAE represents a valid model of the major
pathophysiologic and regulatory mechanisms underlying anti-
myelin autoimmunity in mammals. EAE can be induced by active
immunization with dominant encephalitogenic epitopes of myelin
together with immunological adjuvants. Alternatively, EAE can be
induced by adoptive transfer of activated encephalitogenic T cells.
Overall, the disease is regulated by many of the same counter-
regulatory molecules (e.g., IL-10, TGF-beta, CTLA-4, PD-1) and
cellular regulatory circuits believed to be important in MS. Hence,
EAE is useful as a testing ground for new experimental vac-
cines designed to drive the inhibitory circuits underlying active,
infectious tolerance.
Three rodent models of EAE were used in our studies, with
each model representing a qualitatively different disease course
and a potentially different underlying immunoregulatory mecha-
nism. Initial studies were performed in Lewis rats which recognize
the 73–87 sequence of myelin basic protein (MBP) as the dom-
inant encephalitogenic epitope. Lewis rats immunized with the
MBP73–87 peptide exhibit an acute monophasic form of EAE
which manifests as an acute ascending paralysis followed by a
spontaneous, complete remission. In some cases, Lewis rats having
an intense initial course of EAE may exhibit a secondary relapse
but this relapse is characterized by very mild paralytic signs. In
contrast, the C57BL/6 and SJL mouse models of EAE represent
models of chronic disease. C57BL/6 mice, after immunization
with the myelin oligodendrocyte glycoprotein (MOG)35–55 epi-
tope and separate injections of the Pertussis toxin adjuvant, exhibit
a chronic course of severe non-resolving paralysis. The lack of
spontaneous recovery in C57BL/6 mice may reflect inefficient or
compromised regulatory responses. SJL mice immunized with
the proteolipid protein (PLP)139–151 epitope exhibit a chronic
relapsing-remitting course of EAE. These mice exhibit a severe
monophasic episode of EAE followed by a spontaneous recovery
and a subsequent asynchronous series of relapses and sponta-
neous recoveries. Thus, these cytokine-NAg vaccines were studied
in preclinical models of EAE representing monophasic, chronic-
progressive, and relapsing-remitting courses in rat and mouse
species.
CYTOKINE-NAg FUSION PROTEINS AS TOLEROGENIC,
THERAPEUTIC VACCINES
Our laboratory has focused on a novel strategy for the induction of
tolerance to the major encephalitogenic epitopes of myelin in both
mouse and rat models of EAE (Mannie and Abbott, 2007; Mannie
et al., 2007, 2009b; Blanchfield and Mannie, 2010; Abbott et al.,
2011). The tolerogenic strategy is based on derivation of novel
cytokine-NAg fusion proteins comprised of a native cytokine as
the N-terminal domain fused either with or without a linker to
a C-terminal NAg domain. The structural features of the single-
chain cytokine-NAg fusion proteins are portrayed in Figure 1 and
Table 1. The most effective cytokine domains for induction of tol-
erance were GM-CSF (Blanchfield and Mannie, 2010; Abbott et al.,
2011), IFN-beta (Mannie et al., 2009b), IL-16 (Mannie and Abbott,
2007), and IL-2 (Mannie et al., 2007). In all cases, the cytokine
domains were syngeneic with the species of the EAE model. The
NAg domain contained the dominant epitope of the myelin pro-
tein responsible for induction of EAE in the given species and
strain of rodent. In one case (NAgIL16), the NAg and cytokine
domains were switched as the N-terminus and C-terminus respec-
tively to preserve optimal activity of the cytokine. The cytokine
domains of these vaccines had essentially the full activity of the
free cytokine, and the NAg domain was efficiently processed and
presented on MHC class II (MHCII) glycoproteins to NAg-specific
T cells. Thus, the covalent cytokine-NAg linkage did not inter-
fere with the independent activities of either the cytokine or NAg
domain.
Several fusion proteins had both tolerogenic and therapeutic
activity (Table 2). When injected subcutaneously in saline before
encephalitogenic immunization, GMCSF-NAg, IFNbeta-NAg,
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FIGURE 1 | Structure of cytokine-NAg vaccines. Cytokine-NAg vaccine
structure is portrayed including those incorporating native IL-1RA (IL-1
receptor antagonist), IL-2, IL-4, IL-10, IL-13, GM-CSF, M-CSF, or IFN-beta as
the N-terminus or IL-16 as the C-terminus. Some fusion proteins, as
discussed in theTable 1 legend, contained an enterokinase (EK) linker
sequence.
Table 1 | Selected cytokine-NAg vaccines tested for induction of tolerance in EAE.
Cytokine-NAg
vaccine
Species of
cytokine
EAE
model
NAg
domaina
Optimized
Kozak siteb
Signal
sequenceb
Linkerc Expression
system
GMCSF-NAg Rat Lewis rat MBP69–87 No mouse GM-CSF Not included Baculovirus
GMCSF-NAg Mouse SJL PLP139–151 Yes Native Not included Human
GMCSF-NAg Mouse C57BL/6 MOG35–55 Yes Native Not included Human
IFNbeta-NAg Rat Lewis rat MBP69–87 Yes Native EK linker essential Human
IFNbeta-NAg Mouse SJL PLP139–151 Yes Native EK linker essential Human
NAgIL16 Rat Lewis rat MBP69–87 No HBM Not included Baculovirus
MCSF-NAg Rat Lewis rat MBP69–87 No Native Not included Baculovirus
IL2-NAg Rat Lewis rat MBP73–87 Yes Native Not needed Baculovirus
IL4-NAg Rat Lewis rat MBP73–87 No Native Not needed Baculovirus
aPeptide sequences used in these fusion proteins were: MBP69–87 (YGSLPQKSQRSQDENPVVH); MBP73–87 (PQKSQRSQDENPVVH); MOG35–55 (MEVGWYR-
SPFSRVVHLYRNGK); and PLP139–151 (HSLGKWLGHPDKF).
bFusion proteins used to study rat or mouse models of EAE were rat or mouse in origin, respectively. Mouse GMCSF-NAg, both rat and mouse IFNbeta-NAg, and
rat IL2-NAg contained a non-native alanine as the second amino acid at the N-terminus to optimize a Kozak translation-initiation site (GCCGCCACCATGG). The signal
sequence was the native signal sequence for each cytokine gene product except for rat GMCSF-NAg and NAgIL16 which contained the mouse GM-CSF or the honey
bee mellitin (HBM) signal sequence, respectively. Rat MCSF-NAg was comprised of the 33 amino acid signal sequence plus the 220 amino acid N-terminal domain
which forms a soluble biologically active homodimer. NAgIL16 was comprised of a N-terminal his-tag, the 69–87 encephalitogenic peptide of MBP, and the rat 118-aa
IL-16 cytokine C-terminus.
cA linker between the cytokine domain and the NAg domain was not needed or not included in the primary protein structure with the exception of the IFNbeta-NAg
fusion proteins, where this linker was essential for full expression of IFN-beta activity. For those cytokine-NAg linkers in which the linker was “not needed,” the
vaccine was originally expressed with the linker, but subsequent versions that lacked the linker had full activity in assays of cytokine activity, antigenic activity, and
tolerance induction.
NAgIL16, and IL2-NAg prevented or attenuated the subsequent
active induction of EAE. When administered after onset of EAE,
these vaccines also were effective interventions that blunted the
progression of EAE. Because these fusion proteins had both tolero-
genic (i.e., preventative) and therapeutic (i.e., inhibition of effector
autoimmune responses) activity, these vaccines were referred to
as tolerogenic, therapeutic vaccines. The characteristics of these
vaccines are summarized in Table 2, and two of these vaccines
(GMCSF-NAg and IFNbeta-NAg) are discussed in detail includ-
ing considerations of relative tolerogenic efficacy, requirement
for covalent cytokine-NAg linkage, and differential potency and
subset-specificity in targeting of the covalently tethered NAg
to APC.
GMCSF-NAg
Fusion of GM-CSF with the NAg peptides MOG35–55, PLP139–
151, or MBP69–87 domains did not quantitatively affect the
potency of the GM-CSF cytokine domain (Blanchfield and Man-
nie, 2010; Abbott et al., 2011). Rather, these GMCSF-NAg fusion
proteins were equipotent compared to free GM-CSF in cytokine
www.frontiersin.org August 2012 | Volume 3 | Article 255 | 3
Mannie et al. Tolerogenic, therapeutic vaccines for EAE
Table 2 | Summary of cytokine-NAg vaccines tested in EAE.
Cytokine-NAg
vaccinea
Inhibitory efficacy
in EAEa
Cytokine-NAg linkage
needed for:
Antigenic targeting
to APC in vitroc
Citation
pre-treatment b treatmentb
Rat GMCSF-NAg Yes Yes Yes >1000-fold (myeloid APC) Blanchfield and Mannie (2010)
Murine GMCSF-NAg Yes Yes Yes ∼10-fold (myeloid APC) Abbott et al. (2011)
Rat IFNbeta-NAg Yes No No ∼1 to 10-fold (splenic APC) Mannie et al. (2009b)
Murine IFNbeta-NAg Yes Yes —d —d
Rat NAgIL16 Yes Yes Yes ∼1 to 10-fold (splenic APC) Mannie and Abbott (2007)
Rat IL2-NAg Yes Yes Yes >1000-fold (I-A+ T cells) Mannie et al. (2007)
Rat MCSF-NAg Yes Yes — 10-100 fold (myeloid APC) Blanchfield and Mannie (2010)
Rat IL4-NAg Limited — — >(1000-fold (B cell APC) Mannie et al. (2007)
aCytokine-NAg vaccines exhibited efficacy in both prevention (vaccine administration before encephalitogenic immunization) and therapeutic (vaccine administration
at or after EAE onset) vaccine regimens.
bYes: the cytokine-NAg vaccine was tolerogenic but equimolar doses of cytokine and NAg as separate molecules lacked tolerogenic activity. No: the cytokine-NAg
vaccine had a tolerogenic efficacy similar to that of equimolar doses of cytokine and NAg.
cAntigen-targeting: the “fold” enhancement in antigenic potency of a cytokine-NAg vaccine compared to NAg alone in stimulating MHCII-restricted proliferation of a
NAg-specific T cell clone in the presence of myeloid APC, non-fractionated splenic APC, blastogenic T cell APC, or purified B cell APC.
d(—): Not tested.
bioassays. GM-CSF and GMCSF-NAg elicited equipotent prolifer-
ation of bone marrow cells in the 1–10 pM range. These findings
indicated that GM-CSF is a versatile carrier able to accommo-
date diverse peptide structures without adverse effect on GM-CSF
biological activity.
The tolerogenic activity of the GMCSF-NAg vaccines in mouse
and rat models of EAE (Blanchfield and Mannie, 2010; Abbott
et al., 2011) are portrayed in Figures 2 and 3. These data high-
light the efficacy of each treatment group based on maximal
disease scores. For example, 86% of C57BL/6 mice pretreated with
GMCSF-MOG(35–55) showed no disease whereas mice pretreated
with a combination of GM-CSF and MOG35–55 had severe par-
alytic disease marked by a maximal score of 4.0 or 5.0 (81 and
13% of mice, respectively; Figure 2A). Likewise, over 80% of mice
in control pre-treatment groups that received GM-CSF alone,
MOG35–55 alone, or saline exhibited severe paralytic disease.
Thus, GMCSF-MOG(35–55) had tolerogenic activity because the
vaccine effect was remembered by the immune system as an endur-
ing modification of the MOG-specific encephalitogenic response.
When administered at the first day of clinical onset, GMCSF-
MOG(35–55) was effective as a treatment intervention that halted
the subsequent progression of EAE (Figure 2B). The majority
of mice treated with GMCSF-MOG did not progress beyond a
grade of minimal tail involvement, whereas 100% of mice treated
with saline exhibited severe hind-limb paralysis. In this treat-
ment protocol, GMCSF-MOG(35–55) was more effective than
“MOG35–55 alone” which in turn was more effective than saline.
These data indicate that GMCSF-MOG(35–55) could also inter-
cept the encephalitogenic response during the staging of an attack
on CNS myelin. To test the generality of this approach, a murine
GMCSF-NAg vaccine was also derived for the SJL EAE model
that incorporated the PLP139–151 encephalitogenic peptide as the
NAg rather than MOG35–55 (Figure 2C). Subcutaneous injection
of GMCSF-PLP(139–151) in saline was shown to prevent EAE in
88% of SJL mice. The remaining GMCSF-PLP pretreated mice
had very mild paralysis that was limited to the tail. In contrast, a
substantial percentage (≥50%) of mice pretreated with PLP139–
151 or saline had severe paralytic disease. These data revealed that
GMCSF-NAg vaccines were tolerogenic vaccines in two separate
murine models of EAE.
The original study of GMCSF-NAg was performed by use of
the Lewis rat model of EAE (Blanchfield and Mannie, 2010).
In this study, GM-CSF was compared to M-CSF as a tolero-
genic fusion partner by deriving fusion proteins in which the rat
GM-CSF or M-CSF was linked to the immunodominant encephal-
itogenic 69–87 epitope of MBP. The GMCSF-MBP(69–87) vaccine
was more tolerogenic than the MCSF-MBP(69–87) fusion protein
(Figure 3). All rats that received GMCSF-NAg had no or very mild
signs of EAE whereas 42% of rats pretreated with MCSF-NAg
exhibited severe paralytic disease (Figure 3A). The finding that
GM-CSF was a more effective tolerogenic fusion partner than M-
CSF provided suggestive evidence that active induction of myeloid
APC was more important than“quiescent maintenance”for induc-
tion of tolerance (Fleetwood et al., 2007; Hamilton, 2008). This
outcome was expected because GM-CSF facilitates MHCII expres-
sion on myeloid APC whereas M-CSF confers viability to the
macrophage lineage but does not maintain MHCII expression
(Blanchfield and Mannie, 2010). GM-CSF promotes differenti-
ation of MHCII+ dendritic cells (DC) whereas M-CSF appears
to be a maintenance factor for quiescent or non-inflammatory
MHCII− macrophages. Because MHCII expression is critical for
presentation of the NAg domain which is in turn critical for induc-
tion of tolerance, induction or maintenance of MHCII expression
may be a requisite activity of tolerogenic fusion partners.
Covalent linkage of the cytokine and NAg domains was nec-
essary for tolerogenic efficacy. All rats pretreated with GMCSF-
MBP(69–87) were protected from severe EAE whereas all rats
that received an equimolar mix of GM-CSF and NAg exhibited
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FIGURE 2 | Mouse cytokine-NAg vaccines were effective tolerogens in
the C57BL/6 and SJL mouse models of EAE. EAE was elicited in
C57BL/6 mice by injection of MOG35–55 in CFA together with separate
injections (200 ng i.p.) of Pertussis toxin on days 0 and 2. EAE was elicited
in SJL mice by injection of PLP139–151 in CFA. EAE induction was on day 0
relative to pre-treatment with designated cytokine-NAg fusion protein or
control proteins (x -axis) on days-21, -14, and -7 (A,C) or treatment on days
13, 15, 17, and 20 (B). Vaccines were administered subcutaneously in saline.
Maximal disease scores were defined as the most severe disease score
exhibited by a mouse throughout the relevant disease course. The mouse
clinical EAE scoring scale was: 0, no disease; 1.0, partial or full paralysis of
the tail or ataxia but not both; 2.0, flaccid paralysis of the tail and ataxia or
impaired righting reflex; 3.0, partial hind-limb paralysis; 4.0, full hind-limb
paralysis; 5.0 total hind-limb paralysis with forelimb involvement. p Values
were calculated by non-parametric ANOVA based on ranked data with a
Bonferroni Post hoc Test. Data analysis for these experiments was
previously reported in (Abbott et al., 2011). Pre-treatment of C57BL/6 mice
was portrayed inTables 1 and 2, pre-treatment of SJL mice was portrayed
inTable 3, and treatment of C57BL/6 mice was portrayed in Table 4 of
Abbott et al., 2011; ***p≤0.001; **p≤0.01; *p≤0.05; for comparisons of
the cytokine-NAg-treated group with the respective control group).
severe paralysis (Figure 3A). When administered after the onset
of clinical signs, GMCSF-MBP(69–87) stopped the progression
of EAE by a mechanism that was contingent upon cytokine-NAg
linkage (Figure 3B). Physical linkage of GM-CSF and MOG35–55
domains was also necessary for tolerance induction in the C57BL/6
model of EAE (Figure 2). Overall, these data show that GM-CSF
is an efficacious tolerogenic fusion partner that facilitates toler-
ance of covalently attached myelin antigens in two distinct rodent
species and in qualitatively different models of EAE. The require-
ment for covalent linkage of cytokine and NAg domains pro-
vides evidence for “antigenic targeting” as a potentially important
event in tolerance induction in both pre-treatment and treatment
regimens.
The tolerogenic potency of GMCSF-NAg was paradoxical given
that GM-CSF is a cytokine closely associated with the induction
of EAE in mice (McQualter et al., 2001), and the NAg determi-
nants represent the most potent and dominant encephalitogenic
determinants for the respective rodent strains (Mannie et al.,
2009a; Miller et al., 2009). Yet, a vaccine generated by the com-
bination of these two pro-encephalitogenic domains comprised
a potent tolerogen. Hence, tolerogenic, therapeutic vaccines are
not simply a sum of their parts. Rather, synergy of two physically
connected domains provides novel activities most likely reflecting
unpredicted interactions between APC conditioning and antigenic
targeting. GM-CSF has been shown to be critical for EAE induc-
tion, but these studies have important caveats in regard to the
target tissue localization of pro-disease activity. Indeed, the abil-
ity of NAg-specific T cells to produce GM-CSF during activation
appears to be a defining, central characteristic underlying T cell-
mediated pathogenesis in EAE (Marusic et al., 2002; Ponomarev
et al., 2007; Kroenke et al., 2008; Becher and Segal, 2011; Codarri
et al., 2011; El-Behi et al., 2011). Localization of GM-CSF to the
target tissue, either elaborated by infiltrating T cells or via genetic
manipulation, defined an essential aspect of how GM-CSF pro-
motes disease in EAE and other autoimmune diseases (Biondo
et al., 2001; Judkowski et al., 2004).
Conversely, administration of GM-CSF inhibits autoimmune
disease in mouse models of type I diabetes (Enzler et al., 2003,
2007; Gaudreau et al., 2007, 2010; Meriggioli et al., 2008; Cheatem
et al., 2009), myasthenia gravis (Sheng et al., 2006, 2008; Merig-
gioli et al., 2008), and thyroiditis (Vasu et al., 2003; Gangi et al.,
2005; Ganesh et al., 2009, 2011; Bhattacharya et al., 2011). GM-
CSF appears to promote differentiation of regulatory DC subsets
which in turn facilitate the activity of regulatory T cell subsets
that actively inhibit autoimmune disease. Administration of GM-
CSF may thereby influence the balance between immunity and
tolerance based on factors such as dose, schedule, route, and
bio-distribution. Overall, GM-CSF appears important for devel-
opment and maintenance of regulatory DC-T cell networks. And
GMCSF-NAg vaccines appear to target NAg to these networks
and thereby cause tolerance rather than immunity to the myelin
self-antigen domains.
IFNbeta-NAg
The potent efficacy of IFN-beta as a tolerogenic fusion part-
ner is notable given that this cytokine is used as a first-line
therapy for MS (Kieseier, 2011; Killestein and Polman, 2011;
www.frontiersin.org August 2012 | Volume 3 | Article 255 | 5
Mannie et al. Tolerogenic, therapeutic vaccines for EAE
FIGURE 3 |The rat GMCSF-MBP vaccine was an effective tolerogen in
the Lewis rat model of EAE. EAE was elicited in Lewis rats by injection
of NAg in CFA on day 0. Designated cytokine-NAg proteins or control
proteins (x -axis) were given as pre-treatments on days-21, -14, and -7
(A) or alternatively were given as treatments after the onset of paralytic
EAE (B) as described in (Blanchfield and Mannie, 2010). Vaccines were
administered subcutaneously in saline. Maximal disease scores were
previously reported in (Blanchfield and Mannie, 2010). The clinical scoring
scale for rats was; 0, no disease; 0.25, distal limp tail; 0.5, limp tail; 1.0,
ataxia; 2.0, partial hind-limb paralysis; 3.0, full hind-limb paralysis. p values
were calculated as described in Figure 2. These data were previously
portrayed inTables 1 and 2 respectively of (Blanchfield and Mannie, 2010).
(***p≤0.001; **p≤0.01; *p≤0.05 for comparison of the respective
treatment groups to that of GMCSF-NAg).
Plosker, 2011; Rudick and Goelz, 2011). The rat IFNbeta-MBP(69–
87) had strong tolerogenic activity, but in contrast to what was
found for GMCSF-NAg and other cytokine-NAg vaccines, an
equimolar mix of IFN-beta and NAg was nearly as effective
as the IFNbeta-NAg vaccine in both pre-treatment and treat-
ment regimens (Figures 4A,B; Mannie et al., 2009b). The lack
of requirement for domain linkage was apparent even when
the two domains were injected in separate but adjacent sites. A
murine IFNbeta-PLP(139–151) vaccine was derived to test the
generality of these findings. The murine IFNbeta-PLP fusion pro-
tein also induced tolerance in a pre-treatment protocol in the
SJL relapsing-remitting model of EAE (Figure 4C). Unlike rat
IFNbeta-NAg however, the murine IFNbeta-NAg required cova-
lently linked cytokine and NAg domains for tolerance induction.
In the IFNbeta-PLP(139–151) pre-treatment group, 100% of mice
had no or very mild EAE,whereas over 50% of mice pretreated with
the combination of murine IFNbeta and PLP139–151 as separate
molecules had severe paralytic EAE. Likewise, mice pretreated with
PLP139–151 alone or saline also exhibited severe paralytic EAE.
Hence, the rat IFNbeta-MBP(69–87) was a notable exception to
the rule that these vaccines required covalently linked cytokine
and NAg domains. Why these particular rat and murine IFNbeta-
NAg had differential requirements for cytokine-NAg linkage is not
known. One cannot conclude that these observations represent a
species difference given that to date only one IFNbeta-NAg fusion
protein vaccine has been tested in each rodent species.
The lack of requirement for covalent linkage in the rat model
could be potentially explained by either a direct or indirect bind-
ing interaction (perhaps via a third party molecule) by which the
peptide became non-covalently associated with IFN-beta. Such an
adventitious event would be considered exceptional. An alterna-
tive possibility is that the two reagents were sequestered in the
same lymphatic drainage where IFN-beta and NAg may synergis-
tically mediate tolerance by a localized or paracrine mechanism.
IFN-beta is known to have pronounced anti-proliferative and
anti-metabolic activity and thereby may impair clonal expan-
sion and differentiation of NAg-specific effector T cells. Perhaps
the potent cytotoxic activity of IFN-beta may inhibit or preempt
NAg-specific clonal expansion and differentiation needed to stage
an encephalitogenic response and may render the NAg-specific
clonotypes anergic or alter their differentiation toward a regulatory
phenotype.
Importantly, this study provides evidence that IFN-beta funda-
mentally alters how the immune system responds to antigen. As
reviewed elsewhere (Mannie et al., 2009b), IFN-beta inhibits EAE
when administered during the immunization or effector phases
of disease. Our studies however indicated that IFN-beta (without
NAg) did not exert modulatory activity in EAE when administered
on days-21, -14, and -7 before encephalitogenic immunization.
Most likely, this pre-treatment protocol had no effect because
IFN-beta was presumably cleared from the body before encephal-
itogenic immunization. The simplest explanation is that IFN-beta
will not shape a T cell repertoire or have lasting effects on adaptive
immunity unless IFN-beta is present concurrently with an antigen
that is driving an immune response. When given with NAg, partic-
ularly in the form of a fusion protein, IFN-beta showed properties
of a tolerogenic adjuvant. That is, in the presence of NAg, IFN-
beta modified immune responsiveness by conferring an enduring
immunological tolerance to that NAg. Thus, this study reveals a
novel adjuvant activity of IFN-beta that was not previously appre-
ciated as a classical IFN-beta activity. Nonetheless, the action of
IFN-beta as a tolerogenic adjuvant is consistent with the efficacy
of IFN-beta as a front-line therapeutic in MS. That is, IFN-beta in
MS patients may act synergistically with myelin-derived endoge-
nous antigens to promote a lasting tolerogenic activity specific for
those antigens. This scenario may provide a rationale for IFN-
beta dose escalation during acute relapses of MS, not only to
contain the inflammatory demyelination, but also to maximize
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FIGURE 4 | IFNbeta-NAg vaccines were effective tolerogens in the
Lewis rat and SJL models of EAE. EAE was elicited in Lewis rats or SJL
mice by injection of the respective NAg in CFA on day 0. Designated
cytokine-NAg proteins or control proteins (x -axis) were given as
pre-treatments on days-21, -14, and -7 (A,C) or alternatively were given as
treatments after the onset of paralytic EAE (B). Vaccines were injected
subcutaneously in saline. The data analysis for experiments shown in (A,B)
was previously reported in Tables 2 and 4 (pre-treatment) and Tables 4 and 5
(treatment) in Mannie et al. (2009b). In the pre-treatment protocol (A),
Lewis rats that were given the combination of IFNbeta+MBP69–88 as
separate injections in adjacent subcutaneous sites had significantly less
severe EAE than rats treated with MBP69–88 alone (p=0.001) or saline
(p=0.011). In the treatment protocol (B), Lewis rats that were given the
combination of IFNbeta+MBP69–88 as separate molecules had
significantly less severe EAE than rats treated IFN-beta alone (p= 0.001),
MBP69–88 (p< 0.001), or saline (p<0.001). (***p≤0.001; **p≤0.01;
*p≤0.05 for comparison of the respective treatment groups to that of
IFNbeta-NAg).
the bioavailability of IFN-beta during a period when NAg may be
released from the CNS into the periphery and would be available
to act synergistically with IFN-beta to promote tolerance against
those myelin-derived NAg.
NAgIL16 AND IL2-NAg VACCINES
NAgIL16 and IL2-NAg were two additional vaccines that had pro-
nounced tolerogenic activity in the Lewis rat model of EAE. Both
cytokine fusion partners were originally chosen based on their
ability to regulate CD4+ T cell biology. IL-16 is a highly con-
served, species-cross reactive cytokine (Keane et al., 1998) that
may associate with CD4 or other cell surface receptors (Mathy
et al., 2000) and has been implicated in chemotaxis of T cells, DC,
and other leukocyte subsets (Cruikshank et al., 2000). However,
many functions attributed to IL-16 are seen only at high con-
centrations, and the true biological function of IL-16 remains a
mystery. IL-16 is synthesized as a large precursor protein and is
cleaved by caspase-3 into a N-terminal portion that is translo-
cated into the nucleus and a C-terminal protein that constitutes
the active secreted IL-16 (Zhang et al., 1998, 2001). IL-16 there-
fore shares characteristics of IL-1-beta, IL-18, and IL-37 in that the
cytokine is liberated in the cytoplasm by proteolytic cleavage of a
large precursor and then secreted to exert biological functions in
the extracellular environment (Takenouchi et al., 2009).
IL-2 was chosen as a fusion partner because IL-2 has a requi-
site role in the maintenance of self-tolerance based on the ability
of IL-2 to promote the differentiation and expansion of regula-
tory T cell subsets (Malek and Bayer, 2004; Fehervari et al., 2006).
For both NAgIL16 and IL2-NAg vaccines, covalent linkage of the
cytokine and NAg domains was required for inhibitory efficacy
in vivo in both pre-treatment and treatment regimens. For these
vaccines, administration of equimolar doses of the free cytokine
and NAg molecules as a mixture of separate molecules did not
cause tolerance. The requirement for covalent linkage of cytokine
and NAg domains provides suggestive evidence for a mechanism
of “antigenic targeting.”
ANTIGEN-TARGETING ACTIVITY OF CYTOKINE-NAg
VACCINES
Several cytokine-NAg vaccines had antigen-targeting activity
(Tables 1 and 2; Figure 5). “Antigenic targeting” was based on the
observation that rat GMCSF-NAg, IL4-NAg, and IL2-NAg vac-
cines were∼1000-fold more potent when compared to NAg alone
in assays measuring the MHCII-restricted presentation of NAg
by DC, B cells, or blastogenic (rat) T cells, respectively (Mannie
et al., 2007; Blanchfield and Mannie, 2010). The following obser-
vations provided important insight into mechanisms by which
cytokine-NAg vaccines targeted the NAg to APC for enhanced
antigen presentation. First, covalent linkage between the cytokine
domain and the antigenic domain was needed for potentiated
antigen recognition. Addition of cytokine and NAg as separate
molecules did not result in enhanced T cell responses. This find-
ing indicated that the cytokine domain did not enhance antigen
presentation of NAg by a generic augmentation of antigen pro-
cessing, MHCII expression, cytokine production, or some other
general aspect of APC activity. Second, the antigen-targeting pro-
file of a given cytokine-NAg vaccine was specific for particular
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FIGURE 5 | Mechanism of antigen-targeting by cytokine-NAg
vaccines. The following sequence of events is postulated to mediate the
conditioning and targeting activities of cytokine-NAg vaccines. First, the
cytokine domain of the vaccine binds to APC subsets that bear the
respective cytokine receptor. Engagement of the cytokine receptor on the
APC triggers a shift from costimulatory activity to a counter-regulatory or
tolerogenic co-inhibitory activity. Engagement of the cytokine receptor
also targets the covalently attached NAg domain to the APC. Ingestion of
cytokine receptor/vaccine complexes into the endosomal compartment
introduces the NAg domain in high concentrations to the MHCII-antigen
processing pathway. Processing of the vaccine liberates the NAg domain
for loading onto nascent MHCII glycoproteins. By this mechanism, APC
that are conditioned by the cytokine domain in turn present high
concentrations of NAg domain on MHCII glycoproteins. Tolerogenic
presentation of the NAg is postulated to induce regulatory elements and
blunt the encephalitogenic immune response.
subsets of APC. GMCSF-NAg was targeted to myeloid APC and
IL4-NAg was targeted to B cells. Antigenic targeting was observed
for IL2-NAg when a rat blastogenic T cell clone bearing high sur-
face densities of MHCII and CD25 was used as APC. In these cases,
IL2-NAg was ∼1000-fold more active as an antigen than the iso-
lated NAg domain. These data are consistent with the hypothesis
that antigen-targeting required a specific interaction between the
cytokine domain of the vaccine and the respective cytokine recep-
tor on the APC surface. Third, antigen-targeting was blocked by
the addition of free cytokine. For example, potentiated antigenic
recognition of GMCSF-NAg was blocked by GM-CSF but not
by M-CSF whereas potentiated antigenic recognition of MCSF-
NAg was blocked by M-CSF but not by GM-CSF (Blanchfield and
Mannie, 2010). Enhanced antigenic recognition of IL4-NAg was
blocked by IL-4 or an anti-IL-4 mAb. Likewise, the enhanced anti-
genic recognition of IL2-NAg was blocked by IL-2 (Mannie et al.,
2007). These findings indicate that the high affinity docking of
the cytokine domain to cytokine receptors on APC was the key
event for potentiated antigen recognition. Lastly, the T cell pro-
liferative response to the cytokine-NAg vaccine was blocked by
MHCII-specific antibodies, indicating that the enhanced T cell
proliferative response was due to MHCII-restricted recognition of
NAg rather than an independent mitogenic activity of the cytokine
domain. These data support the concept that the cytokine domain
of a cytokine-NAg vaccine binds the respective receptors on select
APC subsets to facilitate the uptake of the NAg domain into the
MHCII-antigen processing pathway, where the NAg is liberated
and loaded onto nascent MHCII glycoproteins (Figure 5). The
cytokine receptor-mediated, high affinity, high-capacity uptake of
these vaccines by APC is postulated to account for the enhanced
presentation of NAg to NAg-specific T cells.
Two observations revealed potential associations between
antigenic targeting and tolerance induction. First and most
importantly, most cytokine-NAg vaccines required covalently
linked cytokine-NAg domains for tolerance induction (Table 2).
GMCSF-NAg (both rat and mouse versions), mouse IFNbeta-
NAg, MCSF-NAg, NAgIL16, and IL2-NAg required covalently
linked cytokine-NAg domains for tolerance induction, although
rat IFNbeta-NAg did not, and as discussed above, the reason
for this exception is currently unknown. Second, most vac-
cines showed some degree of antigenic potentiation compared
to NAg alone in assays measuring MHCII-restricted stimulation
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of NAg-specific T cell clones. However, the quantitative magni-
tude of antigenic targeting varied substantially among different
cytokine-NAg vaccines. Rat GMCSF-NAg and IL4-NAg exhibited
profound antigenic targeting in the presence of irradiated splenic
APC, but rat GMCSF-NAg was a potent tolerogen whereas IL4-
NAg lacked tolerogenic efficacy. Given that GMCSF-NAg targeted
NAg to myeloid APC whereas IL4-NAg targeted NAg to B cell APC,
the implication is that the APC subset targeted by the vaccine may
be a critical variable in the efficiency of tolerance induction. These
issues however may be complicated and are currently unresolved.
For example, the ability of IL-4 to confer an immunogenic phe-
notype to DC and target NAg to those DC may counteract any
tolerogenic effects associated with the interaction of IL4-NAg with
B cells.
The antigenic potentiation associated with mouse GMCSF-
NAg, rat NAgIL16, and IFNbeta-NAg (either mouse or rat) was
10-fold or less in the presence of irradiated splenic APC, but
these fusion proteins were effective tolerogens. Thus, antigenic
targeting may be an important component of the tolerogenic
mechanism, at least for certain vaccines, but cannot be consid-
ered a sole factor determining the extent of tolerance induction.
Thus, the cytokine domain, in addition to facilitating antigenic
targeting to certain APC subsets, may also condition the APC to
favor tolerogenic presentation. Overall, the following inter-related
concepts may important for understanding the tolerogenic activ-
ity of cytokine-NAg fusion proteins; (a) the quantitative degree of
antigenic targeting, (b) the APC subset targeted by a given vaccine,
and (c) cytokine-mediated conditioning of that APC subset. Com-
binations of these qualities, and perhaps others not yet realized,
may be central to understanding the mode of action. Given that
GM-CSF, IFN-beta, IL-16, and IL-2 have unique and highly diverse
activities, one cannot assume a common tolerogenic mechanism
for these diverse vaccine products.
ATTRIBUTES OF NAg-SPECIFIC CYTOKINE-NAg VACCINES
THE CYTOKINE DOMAIN AS AN AMPLIFIER OF A TOLEROGENIC
ANTIGEN DOMAIN
All tested cytokine-NAg vaccines had some degree of inhibitory
activity in vivo. Notably, none of the cytokine-NAg fusion pro-
teins augmented EAE (Mannie and Abbott, 2007; Mannie et al.,
2007, 2009b; Blanchfield and Mannie, 2010; Abbott et al., 2011).
In studies by other groups, many of the same cytokine domains,
particularly GM-CSF, were coupled to foreign proteins and were
found to augment immunity to those foreign proteins (Wortham
et al., 1998; Rodriguez et al., 1999; Tso et al., 2001; Wang et al.,
2009; Zhai et al., 2009; van Montfort et al., 2011). At the outset of
this project, the anticipation was that the cytokine domain would
be more important than the antigenic domain for determining the
balance of tolerance versus immunity. However, the opposite pos-
sibility should be considered. The cytokine domain, in part, may
be an amplifier of the intrinsic immunogenic or tolerogenic activ-
ity of the covalently coupled antigenic domain. This may be why
GM-CSF has been used as a fusion partner to augment immu-
nity or tolerance depending on the foreign or “self” origins of
the antigenic domain. The possibility is that cytokines target the
antigenic domain to selected APC subsets for enhanced presen-
tation, and the relative balance of conventional and regulatory T
cells that recognize those epitopes determines the outcomes of
immunity or tolerance. Foreign and self-antigen domains would
be preferentially recognized by conventional and regulatory sub-
sets respectively, and these initial interactions may dictate the type
and scope of the ensuing immune response. The cytokine domain
may also affect the balance of immunity and tolerance through
mechanisms of APC conditioning, and these APC conditioning
events may be reinforced by the relative balance of T cell subsets
that initiate and subsequently dominate the response. In turn, early
T cell biasing events may polarize additional APC and by such a
feed-forward mechanism determine the immunogenic or regu-
latory activities of the overall immune response. Thus, vaccine
activity cannot be predicted simply based on the isolated activ-
ity of the cytokine domain. Rather, the activities of the cytokine,
the antigenic domain, and their interaction, particularly in regard
to mechanisms of APC conditioning, antigenic targeting, and
early biasing of T cell subsets may be the key considerations of
antigen-specific tolerogenic efficacy.
Because a substantial percentage of all cytokine-NAg vaccines
tested in the rat model had significant tolerogenic efficacy, the
extrapolation is that many other highly efficacious cytokine fusion
partners may exist in addition to the ones tested so far in EAE.
Overall, the field of cytokine-NAg vaccines may have substantial
promise for a diversity of chronic inflammatory conditions based
on drug discovery of an expanded set of suitable cytokine fusion
partners. The concept is that many other cytokines may be useful
as fusion partners for the induction of tolerance and that the find-
ings to date simply represent the tip of the iceberg in broaching
the use of cytokine-antigen fusion proteins for the induction of
tolerance.
THE CYTOKINE DOMAIN
The following characteristics of the cytokine domain may favor
induction of tolerance. The cytokine domain should mediate
efficient antigen-targeting to an APC subset associated with the
induction of tolerance. The caveat is that no APC subset is solely
dedicated to tolerance but some may facilitate tolerance more effi-
ciently than others. The cytokine domain should be compatible
with the induction and maintenance of MHCII expression. Con-
versely, cytokines that down-regulate MHCII glycoproteins may be
suppressive but not tolerogenic and may not represent desirable
fusion partners. Cytokines that are highly stable and soluble will
facilitate expression, purity, and yield of the protein. The cytokine
fusion partner should have a C-terminus or N-terminus apart
from the active site so that extension of one terminus with an anti-
genic peptide will not impair cytokine activity. For example, an
IL16-NAg fusion protein (NAg at the C-terminus) was less effec-
tive as a NAg than an alternative version (NAgIL16) that placed
the NAg domain at the N-terminus.
THE NAg DOMAIN
The following characteristics of the NAg domain may favor tol-
erance. The NAg domain should be a dominant encephalitogenic
epitope of myelin, or more broadly, a major autoimmune epi-
tope. The concept of antigen-specific tolerance in autoimmune
disease is contingent upon “hitting the nail on the head.” One
would surmise that targeting minor epitopes would have little
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effect on the autoimmune disease unless such determinants sub-
sequently became important in perpetuating chronic disease. An
inter-related consideration is that the NAg should be“self”to facili-
tate recognition by regulatory T cells which favor self-recognition.
The NAg domain should be soluble to minimize protein aggre-
gation and facilitate expression, purification, and yield of the
recombinant protein. This requirement of solubility for this vac-
cine approach may preclude use of peptide epitopes buried in
transmembrane or hydrophobic domains.
LINKAGE OF THE CYTOKINE-NAg DOMAINS
Most cytokine-NAg vaccines did not require linkers between the
cytokine and NAg domains (Table 1). GMCSF-NAg, MCSF-NAg,
NAgIL16, IL2-NAg, or IL4-NAg did not require an interven-
ing linker for antigen-targeting activity in vitro or for tolerance
induction in vivo. The notable exception was IFNbeta-NAg in
which the enterokinase (EK) linker was needed to preserve full
IFN-beta activity (Mannie et al., 2009b). Direct linkage of IFN-
beta to the MBP69–87 peptide or conversely, placement of the
MBP peptide at the N-terminus resulted in a vaccine character-
ized by substantial losses of IFN-beta potency. Two considerations
should guide research on optimal linker usage in future cytokine-
NAg vaccines. First, one would want to avoid extraneous foreign
linker sequences, unless necessary for full cytokine domain activity,
because such linkers may be immunogenic and elicit neutral-
izing antibody against the vaccine. Second, the use of linkers
with protease-recognition sites may facilitate cleavage and release
of the NAg domain in the MHCII-antigen processing pathway
and thereby facilitate antigen-targeting and tolerogenic activity of
these vaccines.
ROUTE OF ADMINISTRATION
Administration of antigen in the absence of adjuvants or
co-stimulation has long been associated with the induction of
tolerance in many experimental systems including EAE. Myelin-
derived peptides and proteins have been administered by nasal,
oral, or other mucosal routes, and these routes of NAg administra-
tion often result in myelin-specific tolerance capable of blocking
EAE (Shi et al., 1998; Miyamoto et al., 2005; Song et al., 2006;
Weiner et al., 2011). Other tolerance induction strategies appear
contingent upon intravenous delivery of antigen. For example,
antigen-coupled leukocytes were highly tolerogenic when deliv-
ered intravenously but were immunogenic and promoted EAE
when injected by a subcutaneous route (Getts et al., 2011). Other
routes of administration also favor tolerance induction. For exam-
ple, application of myelin antigen on epicutaneous patches elicited
active regulatory mechanisms that inhibited EAE (Bynoe et al.,
2003). Intrathymic injection of myelin antigen augmented induc-
tion of tolerance and inhibited EAE (Khoury et al., 1993; Goss
et al., 1994). These data indicate that soluble protein/peptide anti-
gens may induce tolerance by mechanisms contingent on route
and may lack effectiveness or tolerogenic potency when delivered
via a subcutaneous route.
Subcutaneous administration can have important advantages.
Avoidance of the intravenous route should minimize the prospect
of adverse anaphylactic reactivity. Administration via a subcu-
taneous route, as opposed to mucosal or cutaneous application,
should aid accuracy in dosing. Because cytokine-NAg vaccines
are intended to be given as a limited number of applications, the
ease-of-use benefits of mucosal application are minimal. Admin-
istration in saline without adjuvants should minimize unintended
immunogenic responses that favor the induction of autoimmune
disease. To date, subcutaneous injection of cytokine-NAg vaccines
has not elicited any sign of local reactivity at the injection site.
The finding that cytokine-NAg vaccines can induce tolerance by
a limited number of low-dose injections precludes the need for
chronic administration and therefore minimizes the likelihood of
eliciting neutralizing antibodies against the vaccine. Thus, a pri-
mary advantage is that these vaccines were effective tolerogens
when given in saline as a limited number of administrations by
the subcutaneous route.
THE ISSUE OF NEUTRALIZING ANTI-VACCINE ANTIBODIES
The issue of neutralizing anti-vaccine antibodies was explored
for GMCSF-NAg, because the generation of anti-GM-CSF anti-
bodies, unlike anti-IFN-beta antibodies, might inhibit EAE, and
confound data interpretation. Several considerations inherent
in the experimental approach minimized the possible produc-
tion of anti-vaccine antibodies, including use of syngeneic “self”
cytokine domains, lack of adjuvant, low-dose administration, and
a limited number of “boosts.” Nonetheless, rat GMCSF-NAg was
expressed from baculovirus-infected insect cultures, whereas the
mouse GMCSF-NAg and all IFNbeta-NAg preparations derived
from mammalian cell culture (human embryonic kidney cells).
Possibly, insect specific-glycosylation of rat GMCSF-NAg may be
sufficiently foreign to evoke antibody against this recombinant
protein, and possibly, by epitope spread, may give rise to anti-
bodies that could neutralize endogenous GM-CSF to inhibit EAE.
However, this was not the case. Pre-treatment with GMCSF-NAg
did not result in detectable antibody against either the GM-CSF
or NAg domain or any aspect of the vaccine protein (including
the histidine-tag). Indeed, subcutaneous treatment of GMCSF-
NAg in an alum adjuvant or in combination with either pertussis
toxin or TNF-alpha did not elicit detectable antibody against the
vaccine protein. Intravenous administration of GMCSF-NAg also
did not elicit anti-vaccine antibody. Even high doses (five injec-
tions of 8.0 nmol GMCSF-NAg) did not elicit detectable antibody.
Immunization of rats with NAg/CFA elicited antibody against
the NAg peptide that cross-reacted against the NAg domain of
GMCSF-NAg, but this antibody did not interfere with the thera-
peutic activity of GMCSF-NAg in EAE. The lack of anti-GM-CSF
antibody production was not surprising, because GM-CSF was a
self protein, and the GMCSF domain lacked the necessary adju-
vant activity for immunogenic responses or EAE induction. Thus,
our data to this point indicated that anti-GMCSF antibody played
no substantial role in the inhibitory activity of GMCSF-NAg.
VACCINE-MEDIATED INHIBITORY ACTIVITY IN PRO-INFLAMMATORY
ENVIRONMENTS
GMCSF-NAg was shown to inhibit the effector phase of EAE
(Figure 2B). In this experiment, treatment was initiated when
the first mice began to show initial signs of EAE. At this point
though, a majority of mice remained clinically normal but disease
onset was imminent because, in the next 2 days, seven of eight
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mice developed EAE in the saline-treated group. Treatment with
GMCSF-MOG halted progression of EAE in all mice including
those showing early signs of EAE. This experiment did not how-
ever address whether GMCSF-MOG, delivered subcutaneously in
the flank, could down-regulate effector cells already entrenched
within the CNS to inhibit established EAE. The experiment shown
in Figure 6A was designed to address this question. Treatment with
GMCSF-MOG was initiated in a group of mice showing 100%
disease incidence and an average severity score of greater than 2.
Here again, treatment with GMCSF-MOG reversed the course of
EAE and blocked disease progression over the next 3 weeks, even
after cessation of treatment. This observation provided evidence
that GMCSF-MOG has lasting inhibitory activity despite ongoing
inflammation in the CNS.
A common assumption is that quiescent, non-inflammatory
environments enable tolerogenic responses whereas pro-
inflammatory environments foster immunogenic responses.
Based on this assumption, a cytokine-NAg vaccine should exert
tolerogenic activity in a quiescent, non-inflamed site but would
exhibit immunogenic activity in an inflamed locale. The credence
of this assumption however may be lacking, given that appre-
ciable frequencies of potentially pathogenic, self-reactive T cells
circulate in most individuals (Elong Ngono et al., 2012), and
pro-inflammatory environments are common in most individuals
due to infectious disease, injury, or vaccination. Yet prevalence of
autoimmune disease is relatively low.
Thus, an important question is whether cytokine-NAg vac-
cines require non-inflammatory environments for induction of
tolerance. For example, if GMCSF-MOG was given to a truly
inflamed tissue, would GMCSF-MOG potentiate EAE rather than
tolerance? One possible explanation for the ability of GMCSF-
MOG to inhibit the effector phase of EAE is that peripheral
injection of GMCSF-MOG positions the vaccine within sterile
non-inflammatory environments of isolated peripheral lymphoid
tissues, separate from the lymphatic drainage associated of the
encephalitogenic CFA emulsion and apart from the inflamed CNS.
To more directly address this question, GMSCF-MOG (in saline)
was given as a single injection immediately adjacent to an active
immunization with MOG35–55 in CFA. These mice were also
injected with Pertussis toxin to elicit EAE. The adjacent injec-
tion of GMCSF-MOG, but not GMCSF-PLP or saline, inhibited
the MOG35–55/CFA sensitization as shown by a lack of EAE in
five of six mice (second column, Figure 6B). The MOG domain
of the GMCSF-MOG vaccine was critical for inhibition, because
GMCSF-PLP had no effect on MOG35–55/CFA sensitization (first
column). Thus, the inhibitory mechanism was MOG-dependent
and antigen-specific. The GMCSF-MOG vaccine was inhibitory
within a lymphatic drainage conditioned by CFA and in the midst
of CFA-conditioned inflammatory responses. These data indicate
that GMCSF-MOG retained regulatory activity within the stag-
ing sites of an encephalitogenic response. Overall, these data do
not readily fit the concept that a generic pro/anti-inflammatory
balance determines the outcome of a tolerogenic vaccination.
A related question was whether GMCSF-MOG had pro-
encephalitogenic activity when given in combination with a
saline/CFA emulsion when no antigen was actually incorporated
into the CFA emulsion (fourth column, Figure 6B). In this case,
FIGURE 6 | GMCSF-MOG was an effective therapeutic in
pro-inflammatory environments. (A) Mice were immunized on day 0 with
200µg MOG35–55 in CFA and were also given Pertussis toxin (200 ng i.p.)
on days 0 and 2. When the majority of mice began showing paralytic EAE,
mice were matched for clinical signs of EAE and were injected with the
synthetic peptide MOG35–55, GMCSF-MOG (2 nmol subcutaneously in
saline), or saline on days 12, 14, 16, and 18 (red arrows). Mean maximal
disease scores of mice treated with GMCSF-MOG significantly differed
from those treated with saline (p=0.015; non-parametric ANOVA based on
ranked scores). (B) On day 0, mice were given an injection of MOG35–55 in
CFA to elicit EAE along with an adjacent injection (∼1 mm apart) of 2 nmol
GMCSF-PLP, GMCSF-MOG (in saline), or saline. A separate group of mice
were injected with a saline/CFA emulsion and an adjacent injection of
2 nmol GMCSF-MOG. All four groups also received Pertussis toxin (200 ng
i.p.) on days 0 and 2. Maximal EAE scores of mice given adjacent injections
of “MOG35–55/CFA and GMCSF-MOG (second column)” or “saline/CFA
and GMCSF-MOG (fourth column)” differed from those for mice injected
with MOG35–55/CFA and either GMCSF-PLP (first column) or saline (third
column; p≤0.001).
the saline/CFA emulsion and the GMCSF-MOG would reach
the same draining lymphatics. One possibility is that the pro-
inflammatory influence of the CFA emulsion would impose a pro-
inflammatory outcome on T cells that recognized the MOG35–55
peptide derived from the GMCSF-MOG vaccine, given that the
CFA antigens and GMCSF-MOG would likely be processed by
many of the same DC. If the CFA emulsion and the GMCSF-MOG
vaccine affect the same subset of DC, then one might predict that
GMCSF-MOG would cause EAE in this experiment. However,
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EAE was not detected in this group. Overall, arguments based
on a generic pro/anti-inflammatory balance are not sufficient
to account for activity of these vaccines. Rather, GMCSF-MOG
has strong inhibitory activity that can directly inhibit encephal-
itogenic responses, even in the midst of a pro-inflammatory
environment.
In contrast to GMCSF-MOG, it is notable that GMCSF-PLP
did not affect EAE (compare first and second columns, Figure 6B)
when given as side-by-side injections with MOG35–55/CFA. The
observation underscores the antigen specificity of cytokine-NAg
vaccines. Importantly, the GM-CSF domain did not augment
EAE when given in the same peripheral drainage site as the
MOG35–55/CFA emulsion. The same result was revealed by exper-
iments comparing GMCSF-NAg to GM-CSF (Figures 2A and 3B).
Peripheral administration of low-dose GM-CSF did not augment
an encephalitogenic response. According to these experiments,
administration of GM-CSF in limited doses at peripheral sites
in wildtype mice does not augment EAE. These findings show
that peripheral administration of GM-CSF does not feed the
pro-encephalitogenic CNS actions of GM-CSF. Indeed, periph-
eral administration of exogenous GM-CSF inhibits autoimmune
disease by facilitating differentiation of homeostatic DC-Treg net-
works (Enzler et al., 2003, 2007; Vasu et al., 2003; Gangi et al.,
2005; Sheng et al., 2006, 2008; Gaudreau et al., 2007, 2010; Merig-
gioli et al., 2008; Cheatem et al., 2009; Ganesh et al., 2009, 2011;
Bhattacharya et al., 2011).
These observations underlie a paradox. The GM-CSF domain
of GMCSF-MOG is an optimal fusion partner for inhibition of
EAE whereas GM-CSF, produced by re-activated CNS-infiltrating
T cells, is needed for effector responses of EAE in the CNS (Marusic
et al., 2002; Ponomarev et al., 2007; Kroenke et al., 2008; Becher and
Segal, 2011; Codarri et al., 2011; El-Behi et al., 2011). One possible
explanation for this paradox is that the GMCSF-MOG vaccine acts
in peripheral lymphoid tissues to inhibit the generation of MOG-
specific T cells needed for induction of EAE, thereby accounting
the pre-treatment efficacy of the vaccine. GMCSF-MOG may also
impair generation of MOG-specific T cells needed for the main-
tenance or replenishment of CNS-resident T cells during chronic
EAE, thereby explaining the treatment efficacy of the vaccine. In
both cases, GMCSF-MOG may be acting peripherally to mitigate
disease of the CNS. Conversely, the elaboration of the GM-CSF
cytokine in the CNS target tissue may be needed for phagocytic
destruction of myelin during the effector phase of EAE. Inhibitory
and encephalitogenic activities of GM-CSF are not contradictory,
but rather may merely reflect different aspects of GM-CSF in dif-
ferent places at different phases of the immune response. That is,
GM-CSF in peripheral sites including secondary lymphoid organs
may be homeostatic whereas GM-CSF acting centrally in the CNS
may be pathogenic.
ROLE OF MYELOID APC AND DC IN ANTIGEN-SPECIFIC TOLERANCE
The use of antigen to induce antigen-specific immunological
tolerance has been extensively studied over many decades and
represents the basis for development of directed therapies for
autoimmune disease and other allergic or inflammatory disorders.
For autoimmune disease, the simplest reductionist approach is to
use a cocktail of peptides representing the major autoantigens that
are suspected of driving the autoimmune process (Wraith, 2009).
Many variations on this theme exist, including incorporation of
DNA sequences encoding major autoantigens into DNA based
vaccines (Steinman, 2010). Autoantigen peptides have been cou-
pled to leukocyte cell surfaces, and leukocyte-antigen preparations
have been shown to exert tolerogenic activity that prevents autoim-
munity and hypersensitivity in rodent models of disease (Turley
and Miller, 2010). For peptide and DNA vaccines, DC or related
myeloid-derived APC appear to be pivotal APC for induction of
tolerance. For cell-based vaccines, myelin peptides are coupled to
leukocytes by means of a fixative which causes apoptosis, and tol-
erance appears dependent upon uptake of apoptotic donor APC by
recipient myeloid-derived APC followed by reprocessing and pre-
sentation of the myelin antigens by splenic macrophages. These
antigen-based approaches have now progressed into clinical trials
to assess safety and efficacy.
Our experiments consistently show that cytokine-NAg vaccines
are qualitatively superior to the free antigenic peptide for induc-
tion of tolerance and inhibition of autoimmunity (Figures 2–4 and
6A). Free antigenic peptides in some cases had some inhibitory
activity, but based on the delivery regimens used in our stud-
ies, auto-antigenic peptides were useful primarily as “negative”
controls. Likewise, comparison of a multivalent concatemer com-
prising of a linear array of MS-relevant epitopes was substantially
more tolerogenic than the individual peptides (Kaushansky et al.,
2011). The enhanced efficacy of the multi-epitope protein most
likely reflected, in part, protection from proteolysis, enhanced
uptake, and perhaps altered processing by APC. These factors likely
facilitated a greater exposure of the vaccine to the immune system
and thereby promoted more efficient homeostatic regulation of
the relevant autoreactive T cell clones.
Several approaches have been devised to develop tolerogenic
fusion proteins that incorporate autoantigen into larger carrier
proteins. These fusion proteins are designed to target autoanti-
gen into the antigen processing pathways of specialized APC
to enhance MHCII-restricted antigen presentation to thereby
optimize tolerogenic potency and efficacy. For example, myelin
peptides have been incorporated as the CDR3 region of the
immunoglobulin heavy chain (Legge et al., 2001; Divekar et al.,
2011). These Ig-antigen fusion proteins, when appropriately
aggregated and multimerized, interact with low affinity, counter-
regulatory Fc-gamma receptors (i.e., CD32) to target antigen
for enhanced presentation by a mechanism that results in tol-
erance to those myelin antigens. Likewise, B lymphocytes were
engineered to express immunoglobulin-autoantigen fusion pro-
teins. When introduced into mice, these engineered B cells were
able to suppress a number of autoimmune diseases including
EAE by an antigen-specific mechanism associated with the pre-
sentation of endogenously processed peptides on MHCII glyco-
proteins in the context of B7.2-mediated co-stimulation (Melo
et al., 2002; Xu and Scott, 2004; Zhang et al., 2010). The role
of B cells as potentially tolerogenic APC was supported by the
observation that specific targeting of encephalitogenic myelin
peptide to B cells in vivo inhibited the subsequent induction
of EAE (Day et al., 1992; Saoudi et al., 1995). In these stud-
ies, an encephalitogenic MBP peptide was covalently coupled to
anti-IgD antibodies or F(ab’)2 anti-IgD. These antigen-anti-IgD
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Table 3 | Summary of cytokine-NAg vaccines.
Attribute Utility
ATTRIBUTES AND UTILITIES OF CYTOKINE-NAG VACCINES
Antigen-specific induction of tolerance Alleviate need for broad-spectrum immunosuppressive drugs
Long-lasting protection Alleviate need for chronic administration
Potency and efficacy in pre-treatment regimens Vaccines inhibit staging of disease
Potency and efficacy in treatment regimens Vaccines block the effector phase of disease
Effective subcutaneous administration in saline Route of vaccination safe and practical
Three injections sufficient to inhibit EAE Short-term administration minimizes induction of neutralizing antibodies
No adverse reactions at the injection site No recall inflammatory response or Arthus reaction
Small stable proteins, robust expression systems Readily expressed and purified, small proteins have advantageous tissue penetrance and
bio-distribution
IFN-beta re-purposed as a cytokine domain for
myelin-specific vaccines
Extensive clinical experience with IFN-beta as a front-line therapeutic for MS
GM-CSF re-purposed as a cytokine domain for
myelin-specific vaccines
Extensive clinical experience with GM-CSF for bone marrow engraftment and stem cell
mobilization
proteins were therefore designed to bind to most B cells with-
out interference from secreted antibody and without diversion
to Fc receptors. These proteins were used to show a relationship
between B cell-targeted antigen presentation and tolerance induc-
tion. Overall, these experimental systems reinforce the concept that
myelin-derived “self” antigens can be targeted to specialized APC
subsets to efficiently introduce those antigens into the MHCII-
antigen processing pathway to reinforce self-tolerance and blunt
autoimmunity.
In addition to B cells, myelin antigens targeted to DC also
suppress EAE. Myelin peptide antigens have been incorporated
into the C-terminus of immunoglobulin molecules specific for
cell surface molecules on DC such as DEC-205 (Hawiger et al.,
2004; Stern et al., 2010). The incorporation of either MOG35–55
or the PLP139–151 peptide at the C-terminus of an anti-DEC-
205 antibody resulted in the targeted presentation of those myelin
peptides by DC and induction of tolerance and prevention of EAE.
Pre-treatment of C57BL/6 mice with the anti-DEC-205-MOG
fusion protein prevented the subsequent induction of EAE and
induced unresponsiveness in MOG-specific T cells by a mech-
anism associated with enhanced expression of CD5 on anergic
T cells. Pre-treatment with the anti-DEC-205-PLP fusion pro-
tein attenuated the subsequent course of EAE in association
with anergy of PLP effector cells and emergence of regulatory
CD4+T cells. Together with our studies of GMCSF-NAg in
rat and mouse models of EAE, these data provide suggestive
evidence that targeting “self” myelin peptides to DC in vivo
results in antigen-specific tolerance coupled with inhibition of
EAE. GMCSF-NAg is of interest because the vaccine is rela-
tively small in size and has robust activity when administered
after disease onset. The small size facilitates protein expression
and may be advantageous in terms of tissue penetrance and
bioavailability.
It is interesting to note that myelin antigens targeted to major
APC subsets such as B cells and DC resulted in tolerance able
to suppress EAE in various models. Nonetheless, B cells and DC
are critical APC cell types that underlie immunogenic responses
against infectious agents. The major APC subsets of the immune
system therefore do not appear dedicated to either tolerogenic
or immunogenic outcomes. Rather, the functional outcome is a
complex interplay among many poorly understood factors includ-
ing the nature of the antigen (self versus non-self) and the
carrier and their interaction with the local and systemic envi-
ronment. Despite this complexity, it is becoming evident that
new classes of experimental vaccines can be designed to target
major APC subsets to efficiently induce antigen-specific toler-
ance and thereby control autoimmune and other inflammatory
diseases.
CONCLUSION
Cytokine-NAg vaccines represent a novel approach for the induc-
tion of antigen-specific tolerance and may be useful as a ther-
apeutic approach for MS. This approach has numerous advan-
tages as reviewed in Table 3. This vaccine approach may also be
applied to develop therapeutics for other autoimmune diseases.
This approach to date has only been superficially explored and
requires future research to understand the underlying tolerogenic
mechanisms, to test an expanded number of tolerogenic cytokine
fusion partners and myelin epitopes, and translate the concept
to the derivation of optimal human cytokine-NAg vaccines for
treatment of MS.
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